AsclepiX Therapeutics: Private, ophthalmology focused early stage company; technology out of Johns Hopkins. Planning 4Q19 IND and 1Q20 Ph1/2 initiation (DME and Wet AMD). AXT107: novel peptide inhibiting VEGF and activating Tie2; demonstrated efficacy and durability in rabbit and mouse models.
Sector/industry:
Biotech Company
Characteristics:
Listing
Private
Website:
Address:
301 West 29th Street
Suite 2004
Baltimore, MD 21211
United States

Company Participants at AsclepiX Therapeutics KOL Lunch New York

  • Wendy Perrow, MBA, CEO

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.